Journal
Leukemia & Lymphoma
Publication Date
11-1-2022
Volume
64
Issue
1
First Page
130
Last Page
139
Document Type
Open Access Publication
DOI
10.1080/10428194.2022.2136956
Rights and Permissions
Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leuk Lymphoma. 2023 Jan;64(1):130-139. doi: 10.1080/10428194.2022.2136956. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Recommended Citation
Kuruvilla, John; Bartlett, Nancy L; and et al., "Pembrolizumab for patients with non-Hodgkin lymphoma: Phase 1b KEYNOTE-013 study." Leukemia & Lymphoma. 64, 1. 130 - 139. (2022).
https://digitalcommons.wustl.edu/oa_4/3440
Additional Links
Supplemental material is available for this article at publisher site.
